<SEC-DOCUMENT>0002007191-25-000075.txt : 20251217
<SEC-HEADER>0002007191-25-000075.hdr.sgml : 20251217
<ACCEPTANCE-DATETIME>20251217160657
ACCESSION NUMBER:		0002007191-25-000075
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251217
FILED AS OF DATE:		20251217
DATE AS OF CHANGE:		20251217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Telix Pharmaceuticals Ltd
		CENTRAL INDEX KEY:			0002007191
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42128
		FILM NUMBER:		251579307

	BUSINESS ADDRESS:	
		STREET 1:		55 FLEMINGTON ROAD
		CITY:			NORTH MELBOURNE
		STATE:			C3
		ZIP:			3051
		BUSINESS PHONE:		61 3 9093 3855

	MAIL ADDRESS:	
		STREET 1:		55 FLEMINGTON ROAD
		CITY:			NORTH MELBOURNE
		STATE:			C3
		ZIP:			3051
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>k6prostupdate.htm
<DESCRIPTION>CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
<TEXT>
<!-- Created by CompSci Resources, LLC on Wed Dec 17 20:59:35 UTC 2025 --><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: 'Times New Roman'; font-size: 12pt;">
  <div style="font-size: 10pt;">&#xa0;
  </div>
  <div style="text-align: center;">
   <font style="font-size: 14.0pt; color: #000000; font-weight: bold;">UNITED STATES</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 14.0pt; color: #000000; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font>
  </div>
  <div style="text-align: center;">
   <font style="color: #000000; font-weight: bold;">Washington, D.C. 20549</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 18.0pt; color: #000000; font-weight: bold;">FORM 6-K</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">&#xa0;</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">For the month of December, 2025</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">Commission File Number: </font><font style="font-size: 10.0pt; color: #000000; font-weight: bold;">001-42128</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 24.0pt; color: #000000; font-weight: bold;">Telix Pharmaceuticals Limited</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">(Translation of registrant&#x2019;s name into English)</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">55 Flemington Road</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">North Melbourne, Victoria 3051, Australia</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">(Address of principal executive offices)</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">Form 20-F </font><font style="font-family: Segoe UI Emoji; font-size: 10.0pt; color: #000000;">&#x2612;</font><font style="font-size: 10.0pt; color: #000000;"> Form 40-F </font><font style="font-family: Segoe UI Emoji; font-size: 10.0pt; color: #000000;">&#x2610;</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
  </div>
  <div>
    <hr style="width: 100%; height: 1.5pt; background-color: black; border: none; margin-left: 0; margin-right: auto;">

  </div>

  <div style="width: 100%; font-family: &quot;times new roman&quot;; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="display: none; text-align: center">1</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 4px; color: black; background-color: black; display: none;"></div>
<div class="header">&#xa0;</div></div><div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">INFORMATION CONTAINED IN THIS FORM 6-K REPORT</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">On December 17, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled &#x201c;ProstACT Global Study Status,&#x201d; which is attached to this Form 6-K as Exhibit 99.1.</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; width: 8.66%; background-color: #CCEEFF; vertical-align: middle;">
     <div>
      <font style="font-size: 10.0pt; color: #0000EE; text-decoration: underline;"><a href="prostactpr17.htm" style="-sec-extract:exhibit">99.1</a></font>
     </div>
    </td>
    <td style="padding: 0; width: 91.34%; background-color: #CCEEFF; vertical-align: middle;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">Press release &#x2013; December 17, 2025</font>
     </div>
    </td>
   </tr>
  </table>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
    <hr style="width: 100%; height: 1.5pt; background-color: black; border: none; margin-left: 0; margin-right: auto;">

  </div>

  <div style="width: 100%; font-family: &quot;times new roman&quot;; font-size: 10px; margin-top: 0px; margin-bottom: 0px; text-indent: 0px; font-weight: normal; font-style: normal; text-decoration: none;">
  <div style="display: none; text-align: center">2</div>
  <div style="break-after: page;"><hr style="border: none; width: 100%; height: 4px; color: black; background-color: black; display: none;"></div>
<div class="header">&#xa0;</div></div><div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">SIGNATURES</font>
  </div>
  <div style="text-align: center;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
  </div>
  <div style="text-align: justify;">
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;">
   <tr style="vertical-align: top;">
    <td style="padding: 0; padding-top: 0.75pt; padding-bottom: 0.75pt; padding-left: 1pt; padding-right: 1pt; vertical-align: middle; font-size: 0;">&#xa0;
    </td>
    <td style="padding: 0; padding-top: 0.75pt; padding-bottom: 0.75pt; padding-left: 1pt; padding-right: 1pt; vertical-align: middle; font-size: 0;">&#xa0;
    </td>
    <td style="padding: 0; padding-top: 0.75pt; padding-bottom: 0.75pt; padding-left: 1pt; padding-right: 1pt; vertical-align: middle; font-size: 0;">&#xa0;
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td colspan="2" style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000; font-weight: bold;">Telix Pharmaceuticals Limited</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0; padding-bottom: 1.5pt;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">Date: December 17, 2025</font>
     </div>
    </td>
    <td style="padding: 0; padding-bottom: 1.5pt;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">By:</font>
     </div>
    </td>
    <td style="padding: 0; border-bottom: 1.5pt solid #000000;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">/s/ Genevieve Ryan</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">Name: Genevieve Ryan</font>
     </div>
    </td>
   </tr>
   <tr style="vertical-align: top;">
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
     </div>
    </td>
    <td style="padding: 0;">
     <div>
      <font style="font-size: 10.0pt; color: #000000;">Title: Company Secretary</font>
     </div>
    </td>
   </tr>
  </table>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
  <div>
    <hr style="width: 100%; height: 1.5pt; background-color: black; border: none;">

  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">&#xa0;</font>
  </div>
  <div>
   <font style="font-size: 10.0pt; color: #000000;">&#xa0; </font>
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>prostactpr17.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!-- Created by CompSci Resources, LLC on Wed Dec 17 20:59:35 UTC 2025 --><html>
 <head><meta content="text/html; charset=ASCII">
  <title></title>
 </head>
 <body style="font-family: Arial; font-size: 11pt;">
  <div class="header">
    <div style="text-align: right;">
     <img src="image1.gif" style="width: 155.1pt; height: 64.42pt;"><font style="font-size: 10.0pt; font-weight: bold; font-style: italic;">Telix Pharmaceuticals Limited</font><font style="font-size: 10.0pt; font-style: italic;"><br>ACN 616 620 369 </font>
    </div>
    <div style="text-align: right;">
     <font style="font-size: 10.0pt; font-style: italic;">55 Flemington Road</font>
    </div>
    <div style="text-align: right;">
     <font style="font-size: 10.0pt; font-style: italic;">North Melbourne </font>
    </div>
    <div style="text-align: right;">
     <font style="font-size: 10.0pt; font-style: italic;">Victoria, 3051</font>
    </div>
    <div style="text-align: right;">
     <font style="font-size: 10.0pt; font-style: italic;">Australia</font>
    </div>
    <div>&#xa0;
    </div>
    <div style="text-align: right;">
     <font style="font-weight: bold;">ASX ANNOUNCEMENT</font>
    </div>
    <div>&#xa0;
    </div>
  </div>
  <div style="line-height: 1.26; text-align: center;">&#xa0;
  </div>
  <div style="line-height: 1.26; text-align: center;">
   <font style="font-size: 14.0pt; color: #000000; font-weight: bold; text-decoration: underline;">ProstACT Global Study: Status</font>
  </div>
  <div style="text-align: center; font-size: 14pt;">&#xa0;
  </div>
  <div style="line-height: 1.26; text-align: justify;">
   <font style="font-style: italic;">Melbourne (Australia) and Indianapolis, IN (U.S.) &#x2013; 17 December 2025</font><font>. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &#x201c;Telix&#x201d;) today provides an update to confirm the current status of the ProstACT</font><font style="color: #000000;"> Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (</font><sup style="color: #000000;">177</sup><font style="color: #000000;">Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). This announcement is provided in response to inaccurate information in market circulation.</font>
  </div>
  <div style="line-height: 1.26; text-align: justify;">&#xa0;
  </div>
  <div style="text-align: justify;">
   <font style="color: #000000;">ProstACT Global is the first Phase 3 trial to combine a PSMA</font><sup style="color: #000000;">1</sup><font style="color: #000000;">-targeted radio antibody-drug conjugate (rADC) therapy administered together with Standard of Care (SOC; abiraterone, enzalutamide or docetaxel) versus SOC alone. </font><font>Telix confirms that it has completed patient enrolment into Part 1 of the study, a safety and dosimetry lead-in, in accordance with the study protocol. </font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-align: justify;">
   <font>Preparation is now underway to complete data lock and read-out. This includes data from each of the three cohorts in Part 1, including the docetaxel cohort which was the final cohort to complete enrolment. As previously disclosed</font><sup>2</sup><font>, data from Part 1 will be presented to the </font><font style="color: #000000;">United States (U.S) Food and Drug Administration (FDA) to ascertain eligibility for U.S. patients to participate in the Part 2 (randomized treatment expansion) portion of the study. Preliminary results from Part 1 of the study will be publicly disclosed at the time of readout and engagement with the FDA. </font>
  </div>
  <div style="text-align: justify;">&#xa0;
  </div>
  <div style="text-align: justify;">
   <font>In accordance with the study protocol, an Independent&#xa0;Data Monitoring Committee&#xa0;(IDMC)&#xa0;has reviewed the available data in Part 1&#xa0;of the&#xa0;study and, per the IDMC charter, has recommended that the study proceed to Part 2. Accordingly, Telix has advanced the study into Part 2, in jurisdictions where it has obtained approval from health authorities. Part 2 has been initiated on the basis that Part 1 indicates no unexpected safety or clinical characteristics that differ from prior experience. </font>
  </div>
  <div>&#xa0;
  </div>
  <div style="text-align: justify;">
   <font style="color: #000000;">Part 2 of ProstACT Global has dosed its first patients, and is approved and </font><font>open for enrolment in Australia, New Zealand and Canada. The study has also received regulatory approval to commence in China, Singapore, T&#xfc;rkiye, the United Kingdom, South Korea and Japan</font><sup>3</sup><font>. As part of the further global expansion of the trial, Telix intends to file a clinical trial application (CTA) with the European Medicines Agency (EMA) to enable expansion into EU sites.</font>
  </div>
  <div style="text-align: justify;">&#xa0;
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font style="color: #000000; font-weight: bold;">About ProstACT Gl</font><font style="font-weight: bold;">obal</font>
  </div>
  <div style="text-indent: 0.25pt; margin-bottom: 6.35pt; line-height: 1.21; text-align: justify;">
   <font style="color: #000000;">ProstACT&#xa0;Global (ClinicalTrials.gov ID:&#xa0;</font><font>NCT06520345</font><font style="color: #000000;">) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 30 patients (target enrolment complete); and Part 2, 2:1 randomized global expansion with an overall target enrolment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a&#xa0;</font><sup style="color: #000000;">68</sup><font style="color: #000000;">Ga-PSMA-11 PET</font><sup style="color: #000000;">4</sup><font style="color: #000000;">&#xa0;imaging agent (such as Illuccix&#xae;, </font><font>kit for the preparation of gallium-68 (</font><sup>68</sup><font>Ga) gozetotide injection</font><font style="color: #000000;"> or Gozellix&#xae;, </font><font>kit for the preparation of gallium-68 (</font><sup>68</sup><font>Ga) gozetotide injection)</font><font style="color: #000000;"> following prior treatment with an androgen receptor pathway inhibitor (ARPI).</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">1</sup><font style="font-size: 9.0pt;"> P</font><font style="font-size: 9.0pt; color: #000000;">rostate-specific membrane antigen.</font>
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">2</sup><font style="font-size: 9.0pt;"> Telix ASX disclosure 8 December 2025.</font>
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">3</sup><font style="font-size: 9.0pt;">&#xa0;Japanese regulator</font><font style="font-family: Inter; font-size: 9.0pt; color: #0A2E94;">&#xa0;</font><font style="font-size: 9.0pt;">Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2.</font>
  </div>
  <div class="footer" style="page-break-after: always;">
    <div>&#xa0;
    </div>
    <div style="border-bottom: 1pt solid black;">&#xa0;
    </div>
    <div>
     <font style="font-size: 9.0pt;">Page 1</font>
    </div>
    <hr>

  </div>
  <div style="text-align: justify;">
   <font style="color: #000000;">The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small peptide radioligand therapies (RLTs). In contrast to these therapies</font><sup style="color: #000000;">5</sup><font style="color: #000000;">, collective long-term follow-up of patients administered with TLX591 has not observed significant acute or delayed kidney toxicity, as the agent is cleared through the liver, instead of the kidneys</font><sup style="color: #000000;">6</sup><font style="color: #000000;">. TLX591 also demonstrates limited salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs</font><sup style="color: #000000;">7</sup><font style="color: #000000;">.</font><font>&#xa0;</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="line-height: 1.26; text-align: justify;">
   <font>Additional information on the Phase 3 ProstACT Global study can be found at:&#xa0;</font>
  </div>
  <div style="line-height: 1.26; text-align: justify;">
   <font>https://telixpharma.com/prostact/&#xa0;</font>
  </div>
  <div>&#xa0;
  </div>
  <div>&#xa0;
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font style="font-weight: bold;">About </font><font style="color: #000000; font-weight: bold;">Telix Pharmaceuticals Limited </font>
  </div>
  <div style="margin-bottom: 6pt; line-height: 1.26; text-align: justify;">
   <font>Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). </font>
  </div>
  <div style="margin-bottom: 6pt; line-height: 1.26; text-align: justify;">
   <font>Illuccix&#xae;, Telix&#x2019;s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix&#xae; (kit for the preparation of gallium-68 (</font><sup>68</sup><font>Ga) gozetotide injection) has been approved by the FDA</font><sup>8</sup><font>. TLX591 has not received a marketing authorization in any jurisdiction.</font>
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font>Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn</font><font style="color: #0000FF;">,</font><font>&#xa0;X and Facebook</font>
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font style="font-weight: bold;">Telix Investor Relations (Global)</font>
  </div>
  <div style="text-align: justify;">
   <font>Ms. Kyahn Williamson</font>
  </div>
  <div style="text-align: justify;">
   <font>Telix Pharmaceuticals Limited</font>
  </div>
  <div style="text-align: justify;">
   <font>SVP Investor Relations and Corporate Communications</font>
  </div>
  <div style="text-align: justify;">
   <font>Email: kyahn.williamson@telixpharma.com</font>
  </div>
  <div style="text-align: justify;">&#xa0;
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font style="font-weight: bold;">Telix Investor Relations (U.S.)&#x202f;&#xa0;</font>
  </div>
  <div>
   <font>Annie Kasparian&#x202f;&#xa0;</font>
  </div>
  <div>
   <font>Telix Pharmaceuticals Limited&#x202f;&#xa0;</font>
  </div>
  <div>
   <font>Director Investor Relations and Corporate Communications&#x202f;&#xa0;</font>
  </div>
  <div>
   <font>Email: annie.kasparian@telixpharma.com&#xa0;</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="margin-bottom: 6pt; text-align: justify;">
   <font style="font-weight: bold;">Media Contact</font>
  </div>
  <div>
   <font>Eliza Schleifstein</font>
  </div>
  <div>
   <font>917.763.8106 (Mobile)</font>
  </div>
  <div>
   <font>Eliza@schleifsteinpr.com</font>
  </div>
  <div style="font-size: 9pt;">&#xa0;
  </div>
  <div>
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. </font>
  </div>
  <div style="margin-bottom: 12pt; margin-top: 18pt; text-align: center; font-size: 9pt;">&#xa0;
  </div>
  <div>&#xa0;
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">4</sup><font style="font-size: 9.0pt;"> Positron emission tomography.</font>
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">5</sup><font style="font-size: 9.0pt;">&#xa0;Tagawa et al. </font><font style="font-size: 9.0pt; font-style: italic;">Curr Oncol Rep. </font><font style="font-size: 9.0pt;">2021; Steinhelfer et al.&#xa0;</font><font style="font-size: 9.0pt; font-style: italic;">JNM.</font><font style="font-size: 9.0pt;">&#xa0;2024.</font>
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">6</sup><font style="font-size: 9.0pt;">&#xa0;Tagawa et al.&#xa0;</font><font style="font-size: 9.0pt; font-style: italic;">Cancer.&#xa0;</font><font style="font-size: 9.0pt;">2019.</font>
  </div>
  <div style="font-size: 10pt;">
   <sup style="font-size: 6.0pt;">7</sup><font style="font-size: 9.0pt;"> Pepin et al.&#xa0;</font><font style="font-size: 9.0pt; font-style: italic;">Pract Radiat Oncol.</font><font style="font-size: 9.0pt;">&#xa0;2025.</font>
  </div>
  <div class="footer" style="page-break-after: always;">
    <div>&#xa0;
    </div>
    <div style="border-bottom: 1pt solid black;">&#xa0;
    </div>
    <div>
     <font style="font-size: 10.0pt;">Page 2</font>
    </div>
    <hr>

  </div>
  <div style="margin-bottom: 12pt; margin-top: 18pt; text-align: center;">
   <font style="font-size: 9.0pt; color: #7F7F7F;">Legal Notices</font>
  </div>
  <div style="line-height: 1.26; text-align: center;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">Cautionary Statement Regarding Forward-Looking Statements. </font><font><br></font>
  </div>
  <div style="margin-bottom: 8pt; line-height: 1.26; text-align: justify;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.</font>
  </div>
  <div style="margin-bottom: 8pt; line-height: 1.26; text-align: justify;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. &#x202f;To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.</font>
  </div>
  <div style="margin-bottom: 8pt; line-height: 1.26; text-align: justify;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as &#x201c;may&#x201d;, &#x201c;expect&#x201d;, &#x201c;intend&#x201d;, &#x201c;plan&#x201d;, &#x201c;estimate&#x201d;, &#x201c;anticipate&#x201d;, &#x201c;believe&#x201d;, &#x201c;outlook&#x201d;, &#x201c;forecast&#x201d; and &#x201c;guidance&#x201d;, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix&#x2019;s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix&#x2019;s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix&#x2019;s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix&#x2019;s preclinical and clinical trials, and Telix&#x2019;s research and development programs; Telix&#x2019;s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix&#x2019;s product candidates, manufacturing activities and product marketing activities; Telix&#x2019;s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix&#x2019;s product candidates, if or when they have been approved; Telix&#x2019;s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix&#x2019;s expenses, future revenues and capital requirements; Telix&#x2019;s financial performance; developments relating to Telix&#x2019;s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix&#x2019;s business; and the pricing and reimbursement of Telix&#x2019;s product candidates, if and after they have been approved. Telix&#x2019;s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.</font>
  </div>
  <div style="margin-bottom: 8pt; line-height: 1.26; text-align: justify;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the &#xae; or &#x2122; symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.</font>
  </div>
  <div style="margin-bottom: 8pt; line-height: 1.26; text-align: justify;">
   <font style="font-size: 9.0pt; color: #7E7E7E; font-style: italic;">&#xa9;2025 Telix Pharmaceuticals Limited. All rights reserved.</font>
  </div>
  <div>&#xa0;
  </div>
  <div style="font-size: 10pt;">
   <font style="font-size: 9.0pt;">&#xa0;</font><sup style="font-size: 6.0pt;">8</sup><font style="font-size: 9.0pt;"> Telix ASX disclosure 21 March 2025.</font>
  </div>
  <div class="footer" style="page-break-after: always;">
    <div>&#xa0;
    </div>
    <div style="border-bottom: 1pt solid black;">&#xa0;
    </div>
    <div>
     <font style="font-size: 10.0pt;">Page 3</font>
    </div>
  </div>
 </body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image1.gif
M1TE&.#EA.0H_!/<         ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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MRVDJ,YJX;-HO*_),;)J.+-FT9C5/MTWG'',\-1%GYE[BQ$^Z<SS-Z\TXJ:E
M#763GN'TICKSB?_/>UZSG_L,73D?XL]Y%@XLTM2G0D4Y4.6<<TF8\F9-WDE1
M="8GH0 =XH7^R5&#>A2C'07I1_D94GXV5"$%%2GCNC+2E.;SI)TIWD8>"LJ7
M4',G-*TH$YE#TI9N[$(!#>I"2^K2H@HUHT@E:KA@>A"C#I5B75%I3Z6Z3J8V
MQFD>T6D>;8*^<R4EIV"-T7*F2E9?;O2H2GTJ5='J4[66E:VMM"I!G)I4J+*4
MKFE=GUP5L]*.:+51E0FK8"-PG=G559HGV!!>VWK8M[IUL6M]+%OW*A#(.G91
M8)&L9G='6<#0\".#W:ID0OO7>#Z'L:DT45Y7B]K61K:QEHVMU3HKV\?_EN6U
MK*598CO+ET""I+31"RQP!ZL=V%HS1[4U[F9S>UGF)C>"M(5K<^V*%N5:=[>\
MW4MJ04+:_5FFNSJ-@&"V(]TQSNVY+<WN;=!+5;E<EYCJ[4M90S+<6P4(O,\3
M+V;T*][,\->TS\$M?(?&WOG&ES8%[J5?IDNS Q=&LB*IKY[N*V%A\??"_LWP
M?C7<W^TXEX=!2W! '3P;$4N4Q)5R;9A$@E_[<J;%T\'PAF?<7QK+N,;]S3&
MG6-B=*&LQZM$<6R S$LA0ZJ\-1L)C%WL%.S-A+0WCC*'I;QA'>?XRCDNKH"I
M2#(B.]-/HD0R=C'DY6P:V4\?#AN+*XRTH*BT_R70^^^4YVQC.N,8RU7&LI[W
M+%[L(+F!"RNS>54$R.6JF'IB.H^@$8FC, /RT8Z.-*0G+>E*4_K2J;&TIB^]
MZ4YS^M.6!HJ72\)F;N%$LR[1DYSKS.H[VQG#5N:SK&?-Y^L<NH!7A->BQ<B@
M-+]WRQEDSJX'*:1A=_0SAO6UKX5RZP"2>LE'F\F?"2 3'JW:U:VF,K;UG&=:
M>_O;M:[.M"?I+F/CT#Z_9K"ZDXL;<W/Y2,#N,63&W>R9#87>%&0)M+=E.>7B
MI#7:#OBKK]QM<!O\X-X.<+T)QRYWUS \\<;WNB6.P=,X/(522G>""Z-QBG?,
M*!%W=DSVO3F;LC(H __/=H9CC?"6N_SES9FX^ZYU<1"+6]D+SWG(%<F9FHO\
M3!XWM,#NDFR=3UQU1NFX]7)2ZO+5I- ,E<JV8>WJEUO]ZEA?CM!+5RV?Z_4X
M05>ZV''^VL=X?7INVCG9Y=26L.-\*8O^"<E;!AH\8_WN>,][EI%C](Q-Z^R&
MXXW;^SYXM=?[,( 'W5DL:W;";WW,7AE[WYOB^(\9I>E+#(W>-\]YO!='YFJ+
M5N*Y3IO'%Q[T:Q\V7T8O4+,0.==_.3UDKU)TPX<\*I+7;5,P3T+-=_[WP#>X
M;V1_L66QOG>93CWQ3<_\W //+L<GI^N7S[0%1]^!E&_^VZ="_3I)9>Y.KWO_
M\,=/?CWOQOD52];UI3::RBM?^^Z/?U_=LG[JDF7TJY?_NIG]_G1?Q?9[DQ7@
M1SZB47X&6'ZXH7](!RSU1TL]UWT*2&U)T7\4N!8-6#"+!X$RM!=A!G];=A.U
MAWJW!GE6$8&)UA4#&'[B=X LV'D()H*Z9RP7F'Y$1(&3MQ8F"%L9Z($&=EL:
MZ$7R-8-.-C$\B%=?@7XA4Q8I:#]4T5550X(KT8)2J'=#1GTR^(.#]A@PN(6%
MTD98*$[2\X6\-GU%>%Q^88,1%Q)(*'1C\8-KL83Z0Q1JI1)36(=7EVEE^"4,
M*(;$=E4Y&%*4(80]XQ6"B%D^F(?T9!B(R%JP-Q$A_UB(X+*#:]@W< &'3(@3
MRY82=KB)+5<:BRB!O0*)=Y(8HC@PIL&%:+45I7@EDHB&N*08J-A\#<&'_\06
ML>A5=F&)<1@34,=:<,:)P/AMH/&)O[**4!B$MZA4QX@:KEA%6&&,K?B'Y^88
MTKA6N#")C @7 .AW>Z&+%B8A,L82O=A:,Q&,YAANFX&-K!B*M#B-GM6,ZM0;
M0F@5T$B&ZOAEDS&.V]B.^RA]<Q&!A<%[MW)M D=C*9&)8W*."KEWDG&/OE*/
M"_:)& 5V\/A"4P&1]\>/#]<9QJB1.907S8@_ TB0*3=U4Y82;-6(J[*0"SEO
M:/B0'FESO=618]6/U*22</\7DS^7D1)I9J)1C<D8?W\1DHX!7@5IDBI79RS7
M;_4T%2QIC@M 6(OAD.S8DUF8%T#IC,X1E/C8%!@Y%E])&O?(E5QH&&-9&>YT
ME&HY<"PGC"OXE, 7E5@FEQ$0E8<AD3!IE8RF%Q69B- QCUZIDU]WB&-YE:K1
MD7J)DQSGBIY1+R29E$@9F50'?+X'ERY'ESE&EYK97YL)&,28EX6YEW@1FHE)
MFJ;9E\JTC$01EF'!FK)ADZA)2I%QE@5('H\IF24I<,!8F99Y99C)F< I7ILI
MG,%9E\#)@9]9E:?ICG91FK$)FUDIF(QT0=(9>/;XG!LI>-CI<.G(F*<1'&L)
MF;K_V9M]]I; ^)O$F9[&J9[#N9[NN9E1N0!W 61[Z)S,61?V"9WZ29:(^4 Y
MF9_9R9/+^6[&49W[J)KYJ'^R@9OB27#DB7"\.7[H^9[%V9X66J'&"9\96I?N
M)6_U.: !2A<&RI\CVI_;AQ2N^14I^B8DNH@6IX"VL99M^:">9YXO-Z$7RIX8
MJJ/$&9_ Z:- NJ$^VG;[656@N9TR61<ENJ0 :J(>I10K&E5,6GW(H8\MBGYB
M6:2@>!LK1Z.;F)-=:1+?AJ,[2J$\:J9"^J-I&J1LNJ;5193'$J5MUZ13BJ1T
M:I]06J?V!Y9ZZH#RI*5W.HH<V:*^47!>.H6B-EV:F*-H_\JHCKJFD-JFDAJI
M&TH6/:DL<MH6@6JG(.JD:O>?G9JD?+JIUIF G@IZW6F%QG&HP:@3*L82CWJF
M%SJIM$JIM7JK''I7$,@LF4JDT4FJ@!JJP+J.@3FLK4>8G(IVI2>LS%HUDD%D
MRL&JN_DU'P@3L4JAN)JMMKJMVIH5.2@MO=H6R?JKS4JN_<<5X?J,?8J!J3&N
MP7I*U(B7S2&M7_HU"X43L\JM^JJM_+JO4LE]\$@MZ6J+[UID0#.P]+BN--A^
MIWIVL BGSD&O=H@36X2@.^&O_9JQ&*NO4%%FUH*PNG2EU_0S($L5)7L8"INR
MM&.QT&>"V"&QB.H9&ZNQ-#NS0O^J%-*X+B>K%DYZ,CL;%3^;?P4[M")+B7WQ
MB(.G'3 KA3);LTYKL]U*%&)8;BIKB'YAK**:,$'[%%M+246[5E8JBMKEAMRQ
MM"S8M%";MD\[J8GJL;I6M=YGED0;20K3M<5:KHH'BUAKD2@%MSR#%V$;=-]A
MM@:(MFNKMH@KGSKAG'7KMT9:& U+K#KKN)([JGA+>N]HKK)4$9H;IG&1L_%"
MN.3'&8=;NFK[=%]KM(V[MU0ZE>[JDSQE5@G*NNQWG9V+N7R9NL^DAJ\[183R
MA; CNL%'NHE;O!IK4_EI,G;[NY$[B.L5;(ZQO*#:N\C7LK1K0"O1O%MJ@:>)
M'L+[>P'_8KKBNZW>\JLD2[DLBWB7>T^@8;"((;UY>KU^ZA;K^T8W,;=!1;"Z
M.T??NWE)@4 T,;X"[*8H\9P$AKXQI;WDEG]L"!CP.X$(C(/XJT]!4;]9A(.,
MR[_]6Z,\$636:KP@S*8'&8'IVV41#!K4:Y5<*Y@,;,&M*Z I_,*6&\,'1)WR
MRT%H@:0:O,%CJF>*"X( 5<(B,< "K!)"63</_& N3,.W*UO6N\1[&H8WO+!>
M,<6X]G^Z&U1"G+#)Z[T\K)Z96:8_+&W*-%%$G+A&O(^1D\1\A;YN;,4[HYAI
MP<8@=\+>.L$ %190?$0^B,<[?*AD*JMEBHG,Q!-G[+1IC'JM_T/'6JC 3?S&
MN,BS=CS#C^R/  O)Z3*G>\Q"E#RW7KR0UQK*.TH9A[RQY0MLR,/(EI'%<+S)
M116->*RLR%K),LP4K?PY1,?*&16&L5P[X2&A/BS&PBS(.NJCQ$D9(6RSI_Q6
MWJ/*[7?+M,S$\R>NDRS%KOQQ>=K+GHN,V@R[D;>IOWRCP4S,C3K,V(JQDY',
M_)K($SD_SAP;UPS-L3RV\ERYUBS-[#H4W9Q(\U;/4Q,62%N:WB%K@5S.Y)RO
M&FJZDJ'.Y#O"ER1'[ZR=F!S-K]K&_@S+NBS+/3'1__(9^SQ-8&'!VS&7YBS*
M/7K.I6R7D<'0DFK$751.$>T< 1W/-/^-59X1TS^!TQ%1TZ7ZHA_=1R&]M]=Q
MT"6]H2>=TI2ZT"F=O5D[4#H-<1Q]I>U6S:U)U6G4O+H1U5T8TM'W'$1]U&J*
MU,<+&8<\,:)S9EBCU7Z$UFS='12M*-&*TF'-T@P=&0,LCMK3UGJ]UWS=(CQ-
M'&)-UVS;20K-U!74UXB=V(K-(H%KK+@AV) ]V _SM(M=V99]V4?FSR(#&Y'=
MV?'9$QU]%#2+V:1=VJ;])UHM&H&-U#'1AX&QSJ<=V[(]VVNBUHF2SJO-TBX!
M33V!J[3]V\ =W&C2V#QMBH21VW?=$L3MK#Z1U,+]W- =W5%2W"8%%YZMSJC+
MW$8APM+=W=[__=U.\M;)N!7(C<:/,:3@G=[JO=[P9MM(N,4G<=UKR][T7=_V
M/5#477-16-X9>]_^_=\ _DN.O'.P*M_H'. (GN *_D@_O9P%SM^VNN 2/N$4
M_DCBS7@K >&T6N$<WN$>GDDSC<\J]. &WJ8??N(HGN+E9-LMH>$9JN(P'N,R
M3EEUVN(E;IPW$3PSON,\WN,'#'\NP=\Q,88^7N1&?N2D+=\1Q7-(WN1._N1H
MW=GI9$907N56?N6=5<H5'-I8WN5>_N4P5==@/N9D7N;_/;YFGN9JON;>7;QL
M_N9P'N>Q3=ER7N=V?N=\/;-XON=\WN<.%K5^'NB"/N@-U="$?NB(_Y[H%M32
MBM[HCO[HR1.DD#[IE%[ID9.KEI[IFK[IG-[IGO[IH![JHC[JI%[JIG[JJ)[J
MJK[JK-[JE"5"KA[KLC[K18),M'[KN)[K*A)%NM[KOO[K#0)8P#[LQ%[LS0(C
MQI[LRK[L2BLJS/[LT![MOE$YTE[MUG[MI5%RV+[MW-[M1<DRWA[NXC[N>@$]
MY'[NZ)[N9Q%"ZM[N[O[N5'%'\#[O]-[N<6L[>%3O^K[ORPYJF/8IQL3O C_P
MM^YIG39R%47P"K_PJF[PE/9D6L7P$C_QIN[O3$=<%)_Q&D_P%;;Q'O_Q[UYJ
M(#_R)._MO%?R*)_RS"Z0.Q82_N[PH:;R,O\_\PG3&G:T;X8-\R^_\SH?9C3_
M\T /*+8^/N#W,CQ_]#V/]$H?=4'?]$Z_ZPXS0BP/ZRBY]%:?]%A_]9/V]%S?
M]?TA["(Y]3]BUEE?]EIO]FC_\%Z_]FQO'<&5$P8?&-ZXVV=?]VE_]W;/:6V_
M]WQ/&[D#$WEOSS#AC39_U7A_^(&?^(AOM7W?^(XO]?1B<H?_&V)O0I*O^)B_
M^)F_^=O[^)[_^7)!-D->]G)<;80_(&2L^:K/^:R_^*#_^K /%KBS,J<O'9?<
M^KB_^KH/W['?^[Y_\7]#^Y5?-!*\^\:?^R__^\J__#:QBXLQ_*WBP,<__<BO
M)LA/_=A__=J?_=S_O_U77^'>K[HUN?BE/_%T].VU#U&-%_[L#_-0TO[PW_WR
M'__T/__V_[C/7?]ZS[#W?_#[ODD @4O@0((%#1Y$F%#A0H8-'3Z$./!"A(D5
M*5ZTF!'C1HT=.7[T&!+DR(D139Y$F5+E2H8$3KB$^5)F3)HS;=;$>5-G3IX[
M??8$*I/E4*)%C1Y%FE3IR9]-@SYU&A7J5*E5J5ZUFA7K5JU=N7[U&A;L6+$G
MEIY%FU;M6K9MW;Z%Z[8L6;HZX][%BZONWKE1\_X%'%CP8,*%#1]&')CD8I&-
M,2:&O)+Q9,>5*5^V?"'RYK9\/?>MRUGT:-()09_^G!KU:M6M6;]V'1OV_^O2
MM6W?QIU[[6S96'4#YAT\]F_BQ8T?1YY<^4#,S3,OCYS9^73IU4EJAIY=8&_A
MM+5_!\]=?/?QY<F?-Y\>/7GP[=V_AR]PO?J<\5'.Q\_7_G[^_?W_?\LZ 2\;
MC2S"J$-P0 4)!-"X_!X$JD$)!8.P0OHLQ/!"#3/DL*<)/P0QQ*(Z?!!$$C?<
M2D055V2QQ=P6A'$DP]C[*T8;$\0Q(Q=S0['"'7]<J4<A3R1R2".+1#(H()=D
M,KXD\?OOR2,C;+)**Z_$LJ$;M[R(PO$$RS%,+F/,<C0I84.AS"S/G))--]N$
M\\VRU*2S3L3DY(Z_./?TR4X__P14- *.&E/,Q_^ Z^TP0PMEE+) (>/SLT=W
MC!1/2RO%]%(.)^6T4Z,TE<V^3"OUM%133[T/)T(79=6BP?03K5%96Y41U5=!
MS<K6"7$=E5=?>P76*UV')?97[^)#(=@IB66VV3^G0HI669N=M5II#W46+V.I
MS+:_;;]5%EQQ->RV7$#'[<O;<%$TMUUW/Q0K*6L+=7;>:ZU]%ZYU_<J7/W3W
M!?A?@>GJMV F!PX+P("_-+AAAX]#3=Y[[\W67HM;?7BWA6_*.,J-/T889)$Y
M[KAD"4/NRL21QS*Y99<1:TVIB?&M>&:;JWTYJ63%S;GGME#VS6>AA_X.Z%Q;
M7/DGHI=F&BF&D[IYXF[_+Z9ZN@@NNGJBJYM>B6>NOX[(:*K )KMLR,2NZDI>
MS6:[;81*7*KJ6<N-6NZ-LKX::[VUWMMMAT#VFVVTH0J\<,/1&IQ?3M$[O/'
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M.4"G=CD770<%(?I[9-=*[*<I[5;O]$US(S E]G*']6NG=?B0MUP7Y]J>-\(
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M0_A]"[>)$HH 3T4IU;B-.S0VFC?V(C2 BPJ(>X1?NTU[-RZ1>Q&+<[>0WO?
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MN>E-T'T1M. %,4@X!O8O@QWTX ?K5C\13A"$)33A"<>V00:BD(4M=.'3[%?
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MKL;F'6]9#IOS#=2$=.1>O-TB#>,*NG0K3N778N,6#>8Y#M;F]-\QC>"!)>>
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MX0TYYI5+]K!EFG.6S.;%<$Z-9S@))G9HA1,VFL:%>8RHUW598_AIJ!O&UN>
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IASOLX0^#.,0B'C&)2VSB$Z,XQ2I>,8M;[.(7PSC&,IXQC6L<M(   #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
